In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback